Blockchain Registration Transaction Record
LIXTE Biotechnology Advances Ovarian Cancer Trial and Proton Therapy
LIXTE Biotechnology Holdings advances lead candidate LB-100 in ovarian cancer trial and grows Liora Technologies subsidiary for proton therapy. Read the latest updates.
This news matters because LIXTE's progress with LB-100 could lead to new treatment options for ovarian cancer and other solid tumors, potentially improving patient outcomes. Additionally, the development of the LiGHT System for proton therapy may offer more precise and effective cancer treatment, broadening the company's impact on oncology. Investors and patients alike should watch these developments as they could reshape cancer care.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x27d4925d7f2929b989fe9e6a952bf760be620232c2c0d575fa7b4af3693e7e1f |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | voltvXqJ-e7479a37bb839cbda27e3ba8558e0f7b |